Celularity Inc. - Class A Common Stock (CELU)

Frequently Asked Questions About Celularity Inc. - Class A Common Stock (CELU)

How can I invest in Celularity Inc.?

Interested investors can invest in Celularity Inc. by purchasing shares of its Class A Common Stock listed on the Nasdaq under the ticker symbol CELU. It's advisable for potential investors to conduct thorough research and consider consulting financial advisors before making investment decisions.

How does Celularity approach clinical trials?

Celularity approaches clinical trials with a focus on safety, efficacy, and patient-centered outcomes. The company conducts rigorous clinical testing to evaluate the performance of its therapies, engaging with regulatory bodies to ensure adherence to ethical and scientific standards during the trial process.

How does Celularity source its cells for therapy development?

Celularity sources its cells from the placentas of healthy live births, a practice that ensures ethical compliance and regulatory approval. The placental cells are processed to create therapies that retain high potency and therapeutic potential, distinguishing Celularity in the field of regenerative medicine.

How is Celularity funded?

Celularity is funded through a combination of public capital raised from its stock offering, private investments, and strategic partnerships with major pharmaceutical and biotechnology companies. This diverse funding approach supports its research and development programs and operational growth.

Is Celularity Inc. publicly traded?

Yes, Celularity Inc. is publicly traded on the Nasdaq under the ticker symbol CELU. The company's stock became available for public trading as part of its efforts to raise capital for its R&D initiatives and to expand its operations.

What are the company's goals for the future?

Celularity aims to advance its pipeline of cell therapies, expand clinical trials, and obtain regulatory approvals to bring its innovative products to market. Additionally, the company seeks to strengthen its position in regenerative medicine and broaden its impact on patient care globally.

What are the key products in Celularity's pipeline?

Celularity has a promising pipeline featuring several investigational therapies, including CYNK-001, an allogeneic natural killer (NK) cell therapy aimed at treating different types of cancer. Other products target degenerative diseases and immune disorders, showcasing the company's diverse therapeutic focus.

What are the potential benefits of Celularity's therapies?

The therapies developed by Celularity have the potential to harness the immune system's innate ability to target and destroy diseased cells while promoting tissue repair and regeneration. By using placental-derived cells, Celularity aims to enhance patient outcomes with innovative treatments that could offer fewer side effects compared to traditional therapies.

What challenges does Celularity face in the biotechnology industry?

Like many companies in the biotechnology sector, Celularity faces challenges such as regulatory hurdles, competition from other biotech firms, and the need for substantial funding for continued research and development. Navigating these challenges is crucial to successfully bringing its therapies to market.

What does Celularity Inc. do?

Celularity Inc. is a biotechnology company that focuses on developing innovative cell-based therapies derived from the placentas of healthy live births. The company's unique approach leverages its advanced technology and expertise in immunotherapy to create therapies for various conditions, including cancer and degenerative diseases.

What expertise does the Celularity scientific team possess?

The Celularity scientific team is composed of experts in various fields, including cellular biology, immunotherapy, and regenerative medicine. The team includes researchers with significant experience in developing and commercializing cell-based therapies, contributing to the company's innovative approaches in treating diseases.

What impact does Celularity hope to make in healthcare?

Celularity hopes to make a significant impact in healthcare by providing breakthrough cell-based therapies that can transform the treatment landscape for conditions that are currently difficult to manage. The company's focus on harnessing the power of the immune system aims to improve patient outcomes and enhance quality of life.

What is CYNK-001?

CYNK-001 is an investigational allogeneic natural killer (NK) cell therapy developed by Celularity, designed to treat various types of cancer. It leverages the power of NK cells to target and kill tumor cells while also modulating the immune response, showing promise in both preclinical and clinical studies.

What partnerships has Celularity established?

Celularity has established several strategic partnerships with leading organizations in the healthcare sector. These collaborations aim to enhance research capabilities, expedite product development, and expand access to innovative therapies to treat patients more effectively.

What regulatory approvals has Celularity received?

Celularity is actively working to obtain regulatory approvals from the U.S. Food and Drug Administration (FDA) for its investigational therapies, including investigational new drug (IND) applications for its leading products. The company is committed to ensuring compliance with the highest regulatory standards throughout its development process.

What type of therapies does Celularity focus on?

Celularity focuses primarily on cell therapies, particularly those derived from human placental cells. The company aims to develop treatments that harness the immune system's potential to treat various diseases, including various forms of cancer and autoimmune disorders.

When was Celularity Inc. founded?

Celularity Inc. was founded in 2017. The company was established to utilize cell therapy technologies in the burgeoning field of regenerative medicine and has since grown rapidly, focusing on both research and development and commercial applications.

Where is Celularity Inc. located?

Celularity Inc. is headquartered in Warren, New Jersey. The company's facility enables it to conduct extensive research and development activities while being centrally located in a region known for its strong biotechnology and pharmaceutical industries.

Who are the key members of Celularity's management team?

Celularity's management team consists of experienced leaders in the biotechnology and healthcare sectors. Notably, the team is led by CEO Dr. Robert Hariri, who co-founded the company and brings extensive knowledge in cell therapy and regenerative medicine.

What is the current price of Celularity Inc. - Class A Common Stock?

The current price of Celularity Inc. - Class A Common Stock is 1.390

When was Celularity Inc. - Class A Common Stock last traded?

The last trade of Celularity Inc. - Class A Common Stock was at 3:59 pm EDT on April 7th, 2025